SEC Form 10-Q Summary
Filing identity: The supplied filing is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It covers the unaudited quarter and six months ended June 30, 2016.
Business Context and Reporting Period
Selecta was a clinical-stage biopharmaceutical company developing synthetic vaccine particle technology to modulate immune responses. Its lead candidate, SEL-212, was in a Phase 1/2 clinical program targeting refractory and chronic tophaceous gout. The company had no approved products or product sales; revenue came from research grants and collaboration agreements.
In June 2016, Selecta completed its initial public offering, converted all outstanding preferred stock into common stock, and became a public company. Shares outstanding were 17.9 million at June 30, 2016 and 18.2 million as of August 8, 2016.
Key Financial Metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Grant and collaboration revenue | $2.0 million, versus $1.2 million | $4.1 million, versus $2.3 million |
| Research and development expense | $6.0 million, versus $5.3 million | $12.6 million, versus $10.3 million |
| General and administrative expense | $2.4 million, versus $2.2 million | $4.8 million, versus $4.1 million |
| Loss from operations | $(6.4) million, versus $(6.3) million | $(13.3) million, versus $(12.1) million |
| Net loss | $(6.9) million, versus $(6.9) million | $(14.4) million, versus $(12.6) million |
| Net loss attributable to common stockholders | $(9.1) million, versus $(8.4) million | $(19.0) million, versus $(15.7) million |
| Loss per common share | $(2.75), versus $(3.93) | $(6.90), versus $(7.36) |
Operating margins were approximately negative 317% for the quarter and negative 325% for the six-month period, reflecting the company’s development-stage cost structure and limited revenue base.
Cash and cash equivalents were $82.6 million at June 30, 2016, compared with $32.3 million at December 31, 2015. Short-term deposits and investments totaled $1.9 million, and restricted cash totaled $0.7 million. The company reported an accumulated deficit of $129.8 million.
Net cash used in operating activities was $15.8 million for the six months, compared with $9.2 million in the prior-year period. Investing activities provided $3.3 million, primarily from maturities of short-term government obligations. Financing activities provided $62.5 million, including $65.1 million of IPO proceeds before offering-cost deductions.
Total loans payable were approximately $11.9 million net of discounts and issuance costs, including $1.8 million classified as current. The term loans had a $12.0 million principal balance, an 8.1% interest rate, interest-only payments through January 2017, and scheduled principal amortization beginning in February 2017.
Material Changes Versus the Prior Comparable Period
- Revenue increased 63% in the quarter and 81% for the six-month period, primarily from higher grant revenue, including the NIDA grant. Collaboration revenue declined because of the timing of research activities.
- Research and development expense increased 13% in the quarter and 23% year to date, driven by clinical development, headcount, testing, and grant-related activity. External SEL-212 spending declined, while discovery and preclinical spending increased materially.
- General and administrative expense increased 8% in the quarter and 17% year to date due to higher patent, accounting, facility, legal, and IPO-related costs.
- Operating cash burn increased by $6.6 million year over year, reflecting higher net losses, receivables, prepaid expenses, restricted cash and IPO-related payables.
- The IPO materially strengthened liquidity. The company received approximately $60.8 million of net proceeds in June and an additional approximately $3.7 million from the underwriters’ partial over-allotment exercise in July 2016.
- All redeemable convertible preferred stock converted into 10.1 million common shares upon the IPO, eliminating the $137.5 million preferred-stock balance reported at December 31, 2015 and producing positive stockholders’ equity of $68.8 million at June 30, 2016.
Guidance, Outlook, Risks and Unusual Items
- Management expected operating losses and expenses to increase as SEL-212 clinical development and other research programs advanced. Product sales were not expected for at least several years, if ever.
- Management stated that cash, cash equivalents, short-term investments and restricted cash were expected to fund operations and capital expenditures into the first quarter of 2018. A risk-factor disclosure separately stated funding was expected through at least December 31, 2017; investors should reconcile this difference.
- Future funding requirements depend on clinical-trial progress, regulatory requirements, manufacturing costs, collaboration milestones and the ability to raise additional equity or debt. Additional financing could dilute shareholders or require restrictive terms.
- Key development risks included the unproven SVP technology, clinical-trial enrollment and safety, regulatory approval, manufacturing dependence, intellectual-property protection, and reliance on collaborators and third-party contractors.
- SEL-212 depended on pegsiticase supplied by 3SBio in China, creating single-source, manufacturing, regulatory, geopolitical and supply-chain risks.
- The $12.0 million secured credit facility contained affirmative and negative covenants, restrictions involving transfers to the Russian subsidiary, and a subjective acceleration clause tied to material adverse changes or collateral impairment.
- Grant funding included amounts subject to audit and potential repayment. Skolkovo funding remained deferred revenue until audit or expiration of the applicable audit period. The company also had approximately $6.6 million of purchase orders under clinical and research agreements, generally terminable upon notice.
- The company entered into a new license agreement with Massachusetts Eye and Ear Infirmary and The Schepens Eye Research Institute in May 2016, involving upfront, maintenance, milestone, royalty and sublicense-payment obligations.
- No material litigation or off-balance-sheet arrangements were reported. Management concluded disclosure controls were effective as of June 30, 2016.
Most Important Facts to Verify
- Confirm that this filing belongs to Selecta Biosciences rather than Cartesian Therapeutics.
- Reconcile the reported cash runway through the first quarter of 2018 with the separate risk disclosure stating funding through at least December 31, 2017.
- Verify the use of IPO proceeds, including the July 2016 over-allotment proceeds and remaining cash after operating burn.
- Monitor SEL-212 Phase 1/2 results, timing of Phase 2 initiation, patient enrollment and reported serious adverse events.
- Review debt covenants, the February 2017 start of principal amortization and the lender’s acceleration rights.
- Assess the collectability, timing and audit requirements of grant and collaboration revenue, including deferred Skolkovo and Minpromtorg-related amounts.
- Evaluate dependence on 3SBio and other third-party manufacturers, as well as the status and scope of intellectual-property licenses and patent protection.